Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

WHITE PLAINS, N.Y., Feb. 19, 2013 /PRNewswire/ -- In 1964, the five-year survival rate for the most common form of childhood leukemia was only three percent but, today, thanks to treatment advances, about 90 percent of children survive. As the leading global non-profit organization dedicated to curing blood cancers, The Leukemia & Lymphoma Society (LLS) has invested nearly one billion dollars in blood cancer research since 1954, bringing us closer than ever to realizing a world without blood cancers.

(Photo:  http://photos.prnewswire.com/prnh/20130219/NY61444 )

LLS has achieved its leadership position through a unique approach to research and fundraising. Its venture philanthropy model forges partnerships with pharmaceutical and biotechnology companies, academia, medical centers and the National Institutes of Health, to foster the process of drug discovery from basic research to translational and clinical research. Rather than duplicate what the federal government is funding, LLS developed its own research agenda to accelerate the development of promising new life-saving therapies with a focus on un-met medical need.

"We're not your grandfather's charity," proclaims Louis DeGennaro , PhD, LLS chief mission officer. "There is no means of preventing or early screening for blood cancers, so our focus is on life-saving research to find cures. LLS research funding has touched the discovery or development of nearly every therapy used in the battle against blood cancers – including targeted drugs, like Gleevec®, Velcade® and Kyprolis™, and immunotherapies, like Rituxan®."

In fact, LLS is playing a unique role in the pathway to cures, especially for a non-profit organization.  Blood cancers, which include leukemia, lymphoma, myeloma and myelodysplastic syndromes, are hema
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... Lenexa, KS (PRWEB) August 19, 2014 ... to offer fast and cost-effective metabolite production from ... and proprietary chemistry platform, the technology enables convenient ... issues. According to XenoTech’s Vice President of ... metabolite synthesis for assessing clinical risk can be ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated ... in a new PSUR – responding to the increasing need ... a drug. Adopted in many regions, the main objectives of ... comprehensive and critical analysis of new or emerging information on ... new evidence of the potential benefits of a drug; and ...
Breaking Biology Technology:Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... , , FLAGSTAFF, Ariz., July 24 ... Australia, New Zealand, Great Britain, Myanmar, the Philippines and Indonesia are ... Radisson Woodlands Hotel to share research findings that will determine the ... , On Sunday morning, Mayor Sara Presler will ...
... ... spaces leased to biotech, pharma and medical devices tenants are faring better in some markets ... ... recession, the credit crunch, pharmaceuticals industry mergers and an overall slump in the commercial property ...
... , , ... PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., today announced ... up to $10 million of the company,s newly issued 10% cumulative convertible preferred ... agreements, the company closed on the issuance of one million preferred shares for ...
Cached Biology Technology:World Renowned Scientists Gather to Share Latest Information on Answer to Wildlife Reproductive Fertility Control 2Life Sciences Real Estate Outperforming Other Sectors 2Life Sciences Real Estate Outperforming Other Sectors 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4
(Date:8/19/2014)... MA -- MIT chemical engineers have devised a new ... are released slowly over a few weeks. When applied ... the body to rapidly form new bone that looks ... type of coated scaffold could offer a dramatic improvement ... involves transplanting bone from another part of the patient,s ...
(Date:8/19/2014)... born with neonatal abstinence syndrome (NAS) secondary to ... going through withdrawal than others, but the underlying ... epigenetic (when genes are turned on or off) ... researchers at Boston University School of Medicine (BUSM) ... of its kind study to identify some of ...
(Date:8/19/2014)... seas during warm phases and became extinct during cold ... a link between marine crocodilian diversity and the evolution ... 140 million years. , The research, led by ... and formerly from the University of Bristol, UK is ... crocodiles are ,cold-blooded, animals that mainly live in fresh ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... , WALL, N.J., Dec. 21 BIO-key International, ... biometric identification solutions, today announced the appointment of Cecilia ... Ceci replaces Tom Colatosti, BIO-key,s Chairman, who had been ... http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , Ceci joined BIO-key in 2007 and ...
... Biometric Society has chosen Springer as the co-publisher of ... (JABES). The quarterly journal will start publication ... 2010. Backfiles to 2001 will be available on ... Journal of Agricultural, Biological, and Environmental Statistics publishes ...
... field, researchers from The University of Western Ontario are studying ... Why is this important? Because the common fruit fly ( ... survive freezing and the little creature just so happens to ... finding a way to freeze them for research purposes is ...
Cached Biology News:BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer 2BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer 3International Biometric Society co-publishes journal with Springer 2The how and why of freezing the common fruit fly 2
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
...
...
Biology Products: